Perrigo (PRGO) Receives FDA Approval for Ciclopirox Topical Suspension
More News related to PRGO
- Perrigo Company to Present at the Credit Suisse 18th Annual Health Care Conference
- Perrigo (PRGO) Tops Q3 Views; Raises FY10 Outlook
- Perrigo Reports Record Earnings and Raises Full Year Adjusted EPS Guidance
- Perrigo Company Divests Israel Cosmetics Business for 205 Million New Israeli Shekels
- Perrigo (PRGO) Decalres $0.0625 Quarterly Dividend; 0.7% Yield
More News related to FDA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
The Perrigo Company (Nasdaq: PRGO) has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Ciclopirox Topical Suspension USP. 0.77% (Lotion).
The product is the AB-rated equivalent to Medicis Pharmaceutical's Loprox Topical Suspension, 0.77%, an antifungal medication indicated for the topical treatment of common skin infections such as athlete's foot, jock itch, and ringworm. According to Wolters Kluwer data, annual sales for the last 12 months were approximately $42 million.
Related Categories
FDAStocks Mentioned
-0.15Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
